Category Archive for Interesting Reads
For opinion pieces and round-ups
Dutch Minister plans to ‘call out’ companies on drug pricing
The Dutch Minister for Medical Care, Bruno Bruins, has said he will ‘name and shame’ companies for charging prices he … read more »
ICER announces consultation on assessment for curative therapies
ICER has opened a consultation on proposed method adaptations for the assessment of potential cures and other transformative therapies. The … read more »
US payers show resistance to gene therapies
Despite recent progress for Zolgensma, the first curative gene therapy licensed in the US, a recent analysis has suggested that … read more »
Shift in White House drug price policy unhelpful for patient access
The Trump administration has announce a shift in its drug pricing policy, cutting an ambitious initiative originally praised by the … read more »
Provocative IQWiG publication in BMJ challenges pharmaceutical innovation model
An article published in the British Medical Journal by IQWiG has argued that over half of new drugs entering the … read more »
DHSC announces AMR reimbursement pilot
The Government has announced some details of an NHS pilot scheme to test an alternative, “subscription” reimbursement model for use … read more »
Could the pay-for-performance model replace rebate negotiations?
Pay-for-performance deals could be replacing rebate negotiations for medicines hinted a GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) representative. … read more »
Study claims drugs prices are likely to continue to increase in the US due to rebate system
A study by Scripps has claimed that drug prices are likely to continue to increase in the US due to … read more »
Irish hospitals may be offered incentives to switch to biosimilars
It has been reported that the Irish HSE is to incentivise hospitals to promote the use of biosimilars in place … read more »
FDA approval of Zolgensma intensifies discussion of payment models for gene therapies
The FDA’s approval of Zolgensma marks the first approval in a new wave of potentially curative gene therapies to reach … read more »
